Close Menu

Mobidiag

The company already offers an antibody test, Anti-SARS-CoV-2 Rapid Test, that it is distributing for its Chinese joint venture partner Autobio Diagnostics.

The Novodiag COVID-19 real-time PCR assay enables on-demand and fully automated detection of early COVID-19 infections in about one hour, the firm said.

Use of the assay by Finland's main clinical laboratories will double testing capacity and allow test coverage for most of the country, Mobidiag said.

A handful of rapid 2019-nCoV assays are in the works which could help triage patients more effectively and avoid unnecessary quarantines.

The new funding supports development of a rapid molecular test to detect bloodstream infections directly from whole blood.

Mobidiag signed agreements for its Amplidiag and Novodiag products with Alab in Poland and the Ukraine; Biogenetix in Romania; and Theranostica in Israel.

The firm said that its newly CE-marked test for intestinal infections is suitable for use in laboratories and hospitals, and provides results in 90 minutes.

The firm's CEO said it is continuing to develop its distributor network to make its tests available in centralized and decentralized settings globally.

Dubbed Automobi Molecular Diagnostics, the company will establish local manufacturing facilities and work to commercialize the Novodiag platform in China.

The four-year loan will be used to develop molecular diagnostic assays for the firm's two test systems, Amplidiag and Novodiag.

Pages

Science reports that a new White House Office of Management and Budget memo rescinds previous ones that helped research institutions deal with pandemic-related closures.

Researchers report on a concerning strain of the H1N1 swine flu virus found among pigs in China, Agence France Presse reports.

The Associated Press reports that US officials are considering allowing pooled COVID-19 testing.

In Genome Research this week: Y chromosome gene expression analysis, de novo mutations rise with paternal age in rhesus macaques, and more.